Finoriq

Finoriq research workspace

Krystal Biotech, Inc. (KRYS) Institutional Holdings & 13F Ownership

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops. Review KRYS institutional holders, 13F ownership, and position changes on Finoriq.

Company Snapshot

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Company
Krystal Biotech, Inc. (KRYS)
Ticker
KRYS
Market Cap
$10.1B
Latest Price
$341.71
Industry
Biotech & Pharma

Open insider transactions

Krystal Biotech, Inc. (KRYS) Top Institutional Holders

Top current 13F holders indexed for Krystal Biotech, Inc. (KRYS). Latest period 2026-03-31.

RankInvestorValuePortfolioFiling
1Ray DalioCIK 0001350694$12M0.05%Filing2026-05-15
2Ken FisherCIK 0000850529$7.2M0.0%Filing2026-05-05
3Torray FundsCIK 0000098758$3.1M0.46%Filing2026-05-01
4Joel GreenblattCIK 0001510387$341,7570.0%Filing2026-05-15

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.